Thank you for your kind words, Dave.
But didn't you go from being a bull to a bear on GENR.
I did—sold at $4 and change last fall for the reasons I posted at the time on iHub.
As a retired ophthalmologist I can vouch that if all things were equal I would rather administer a medication IV than an intrabulbar or peribulbar injection.
Agreed. However, GENR has not yet shown to my satisfaction that Evizon (Squalamine) is likely to be safe and effective. Paradoxically, it concerns me that GENR claims Evizon has no systemic toxicity. Given the MOA—which includes inhibiting angiogenesis—one would expect some mechanistic side effects to show up unless it turns out that the drug doesn’t do much of anything.
Too bad that Squalamine couldn't have gotten to market sooner though.
GENR lost a lot of time fiddling and diddling with the phase-2 program. Back in late 2003, I was hoping they would partner quickly and proceed directly to pivotal phase-2/3 trials. I think they probably could have done this but they overplayed their cards and are now paying the price. By 2009-2010, there may be several AMD drugs on the market, including of course Lucentis.
If GENR continues to go it alone in AMD, they will need to raise a lot more capital. At the right price I would consider buying back in but, for now, I’m just watching.
By the way, I attribute zero shareholder value to GENR’s “programs” in cancer and cystic fibrosis. Regards, Dew |
